PATHWAY-2: spironolactone for resistant hypertension.
3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki 56429, Greece. Electronic address: eugalant@yahoo.com.
Eugenia
E
Gkaliagkousi
3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki 56429, Greece.
Eleni
E
Gavriilaki
3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki 56429, Greece.
Areti
A
Triantafyllou
3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki 56429, Greece.
Stella
S
Douma
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D017298:Bisoprolol / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000627:therapeutic use*
D058668:Adrenergic alpha-1 Receptor Antagonists; D058671:Adrenergic beta-1 Receptor Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D017292:Doxazosin; D017298:Bisoprolol